Data Sheet 3_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 8_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 4_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 5_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Data Sheet 2_Phosphodiesterase 7: a potential novel therapeutic target in ovarian cancer.pdf by Nayara Gusmão Tessarollo (18228556)

“…</p>Results and discussion<p>MTT assays revealed that while BRL 50481 reduced metabolic cellular viability (MCV) in A2780 (IC50 = 200 μM), its combination with PTX decreased MCV in both lines, reducing PTX IC50 by 103- and 625-fold in A2780 and OVCAR3, respectively. …”

Spatial expression pattern of proBcMF26a: GUS-GFP. by Meiling Lyu (767333)

“…<p>(A–L) Histochemical GUS assays of the T₂<i>Arabidopsis</i> transformed with pBGWFS7.0–proBcMF26a: GUS-GFP vector. …”

A novel SNP of <i>MYO1A</i> gene associated with heat-tolerance in Chinese cattle by Yanhong Cao (428443)

Table 1_Evaluating the prognostic relevance of neutrophil-to-lymphocyte ratio in cervical cancer: a systematic review and meta-analysis.docx by Xieyan Zhuang (20467625)

“…Furthermore, elevated NLR significantly impacted disease-free survival (HR: 1.79, 95% CI: 1.18-2.71; p = 0.006), recurrence rates (HR: 2.18, 95% CI: 1.36-3.51; p = 0.001), recurrence-free survival (HR: 3.05, 95% CI: 1.79-5.19; p < 0.0001), and the incidence of distant metastases (HR: 1.73, 95% CI: 1.20-2.50; p = 0.003).</p>Conclusion<p>An elevated NLR prior to treatment demonstrates a strong association with decreased OS and PFS among patients with cervical cancer, underscoring the significance of NLR as a prognostic marker within this population.…”

Simulation Results Plot of the SBW System Response: (a) Step response curve of the SBW system; (b) Sine response curve of the SBW system; (c) Steady state error curve of the SBW sy... by Honglei Pang (22693724)

Polylactic Acid/Polybutylene Adipate Terephthalate-Carbon Nanotube Nanobiocomposites with a Segregated Toughening Morphology Yielding Large Ductility for Biocompatible Materials by Utsab Ayan (18552401)

“…Selective deposition and encapsulation of nanodispersed multiwalled carbon nanotubes (MWCNT) exclusively within polybutylene adipate terephthalate (PBAT) microdomains in a phase-separated microstructure of 80/20 polylactic acid (PLA)/PBAT polymer nanocomposites (PNCs) were achieved by a three-step processing strategy. …”

Table 7_Quality of life in patients with pan-cancer undergoing concurrent chemoradiotherapy: a bibliometric analysis (1995-2024).docx by Ao Shen (127290)

“…Complementarily, a cross-sectional study of 117 cervical cancer patients assessed symptom prevalence via CTCAE v5.0, with symptom clusters identified.…”

Image 1_Quality of life in patients with pan-cancer undergoing concurrent chemoradiotherapy: a bibliometric analysis (1995-2024).tif by Ao Shen (127290)

“…Complementarily, a cross-sectional study of 117 cervical cancer patients assessed symptom prevalence via CTCAE v5.0, with symptom clusters identified.…”

Table 2_Quality of life in patients with pan-cancer undergoing concurrent chemoradiotherapy: a bibliometric analysis (1995-2024).docx by Ao Shen (127290)

“…Complementarily, a cross-sectional study of 117 cervical cancer patients assessed symptom prevalence via CTCAE v5.0, with symptom clusters identified.…”

Table 3_Quality of life in patients with pan-cancer undergoing concurrent chemoradiotherapy: a bibliometric analysis (1995-2024).docx by Ao Shen (127290)

“…Complementarily, a cross-sectional study of 117 cervical cancer patients assessed symptom prevalence via CTCAE v5.0, with symptom clusters identified.…”

Image 6_Quality of life in patients with pan-cancer undergoing concurrent chemoradiotherapy: a bibliometric analysis (1995-2024).tif by Ao Shen (127290)

“…Complementarily, a cross-sectional study of 117 cervical cancer patients assessed symptom prevalence via CTCAE v5.0, with symptom clusters identified.…”

Table 6_Quality of life in patients with pan-cancer undergoing concurrent chemoradiotherapy: a bibliometric analysis (1995-2024).docx by Ao Shen (127290)

“…Complementarily, a cross-sectional study of 117 cervical cancer patients assessed symptom prevalence via CTCAE v5.0, with symptom clusters identified.…”

Image 2_Quality of life in patients with pan-cancer undergoing concurrent chemoradiotherapy: a bibliometric analysis (1995-2024).tif by Ao Shen (127290)

“…Complementarily, a cross-sectional study of 117 cervical cancer patients assessed symptom prevalence via CTCAE v5.0, with symptom clusters identified.…”

Image 5_Quality of life in patients with pan-cancer undergoing concurrent chemoradiotherapy: a bibliometric analysis (1995-2024).tif by Ao Shen (127290)

“…Complementarily, a cross-sectional study of 117 cervical cancer patients assessed symptom prevalence via CTCAE v5.0, with symptom clusters identified.…”

Efficacy and safety of adding gemtuzumab ozogamicin to conventional chemotherapy for adult acute myeloid leukemia: a systematic review and meta-analysis by Yuancheng Guo (10834307)

“…<p><b>Introduction:</b> Compared with the 3 + 7 regimen, the addition of gemtuzumab ozogamicin (GO) has improved survival in patients with acute myeloid leukemia (AML). We conducted a systematic review and meta-analysis to examine the overall efficacy and safety of GO in combination with conventional chemotherapy regimens in patients with AML.…”

Image 3_Quality of life in patients with pan-cancer undergoing concurrent chemoradiotherapy: a bibliometric analysis (1995-2024).tif by Ao Shen (127290)

“…Complementarily, a cross-sectional study of 117 cervical cancer patients assessed symptom prevalence via CTCAE v5.0, with symptom clusters identified.…”